CAS 138681-29-5

Draflazine

CAS : 138681-29-5

Draflazine is a fluorescent derivative of the fatty acid arachidonic acid that binds to the phospholipase A2 receptor. This binding inhibits the release of arachidonic acid from membrane phospholipids and blocks the synthesis of prostaglandins. Draflazine has been shown to increase cardiac function after myocardial infarction, which may be due to its inhibition of reactive oxygen species production and activation of adenosine receptors. The drug also has antinociceptive properties, which have been shown in animal models using nociceptive tests such as tail-flick, hot-plate, and writhing tests. These effects are mediated by G protein-coupled adenosine receptors (A1, A2A).

Formule : C₃₀H₃₃Cl₂F₂N₅O₂

Degré de pureté : Min. 95%

Masse moléculaire : 604.5 g/mol

Ref: 3D-NFA68129